MX2019013210A - Factores de crecimiento recombinantes modificados de fibroblastos y usos terapéuticos de los mismos. - Google Patents

Factores de crecimiento recombinantes modificados de fibroblastos y usos terapéuticos de los mismos.

Info

Publication number
MX2019013210A
MX2019013210A MX2019013210A MX2019013210A MX2019013210A MX 2019013210 A MX2019013210 A MX 2019013210A MX 2019013210 A MX2019013210 A MX 2019013210A MX 2019013210 A MX2019013210 A MX 2019013210A MX 2019013210 A MX2019013210 A MX 2019013210A
Authority
MX
Mexico
Prior art keywords
growth factors
fibroblast growth
therapeutic uses
recombinant modified
modified fibroblast
Prior art date
Application number
MX2019013210A
Other languages
English (en)
Spanish (es)
Inventor
David Eveleth
Jennifer Jenkins-Eveleth
Amuthakannan Subramaniam
Ralph Bradshaw
Original Assignee
Trefoil Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trefoil Therapeutics Inc filed Critical Trefoil Therapeutics Inc
Publication of MX2019013210A publication Critical patent/MX2019013210A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
MX2019013210A 2017-05-05 2018-05-04 Factores de crecimiento recombinantes modificados de fibroblastos y usos terapéuticos de los mismos. MX2019013210A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762502529P 2017-05-05 2017-05-05
US201762502540P 2017-05-05 2017-05-05
US201762584624P 2017-11-10 2017-11-10
PCT/US2018/031189 WO2018204847A2 (en) 2017-05-05 2018-05-04 Recombinant modified fibroblast growth factors and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
MX2019013210A true MX2019013210A (es) 2020-07-20

Family

ID=64016756

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019013210A MX2019013210A (es) 2017-05-05 2018-05-04 Factores de crecimiento recombinantes modificados de fibroblastos y usos terapéuticos de los mismos.

Country Status (12)

Country Link
US (2) US11479591B2 (enExample)
EP (2) EP4621067A3 (enExample)
JP (2) JP2020518287A (enExample)
KR (1) KR20200078425A (enExample)
CN (1) CN111148755A (enExample)
AU (1) AU2018261021B2 (enExample)
BR (1) BR112019023260A2 (enExample)
CA (1) CA3062473A1 (enExample)
DK (1) DK3619324T3 (enExample)
ES (1) ES3041527T3 (enExample)
MX (1) MX2019013210A (enExample)
WO (1) WO2018204847A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4621067A3 (en) 2017-05-05 2025-11-19 Trefoil Therapeutics, Inc. Recombinant modified fibroblast growth factors and therapeutic uses thereof
JP2023532046A (ja) * 2020-06-26 2023-07-26 トレフォイル セラピューティクス，インク． 組換え修飾線維芽細胞増殖因子およびそれを使用した治療
WO2021261946A1 (ko) 2020-06-26 2021-12-30 엘티소재주식회사 헤테로고리 화합물 및 이를 이용한 유기 발광 소자
WO2022241465A1 (en) * 2021-05-14 2022-11-17 Claris Biotherapeutics, Inc. Compositions of growth factor for the treatment of eye disease
CN113289005B (zh) * 2021-07-06 2022-05-31 温州医科大学 rhFGF-21在制备治疗干眼症药物中的应用
WO2023019218A1 (en) * 2021-08-12 2023-02-16 Trefoil Therapeutics, Inc. Modified fibroblast growth factors for treating fibrotic diseases
US12357843B2 (en) 2022-03-25 2025-07-15 Cutera, Inc. Methods of skin treatment with laser light
CN115177717A (zh) * 2022-08-31 2022-10-14 贵州医科大学附属医院 一种治疗眼表及角膜上皮疾病的药物

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552528A (en) * 1986-03-03 1996-09-03 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bovine b-endothelial cell growth factor
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
GB2223496B (en) * 1988-08-08 1992-05-27 British Bio Technology Synthetic gene encoding mature human acid fibroblast growth factor
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
GB9523946D0 (en) 1995-11-23 1996-01-24 Bayer Ag Leukotriene antagonistic benzoic acid derivatives
US20010006939A1 (en) 1997-10-03 2001-07-05 Ralph W. Niven Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions
US6642026B2 (en) * 2000-08-15 2003-11-04 Phage Biotechnology Corporation Method of producing biologically active human acidic fibroblast growth factor and its use in promoting angiogenesis
AU1628101A (en) 1999-11-22 2001-06-04 Millennium Pharmaceuticals, Inc. Jaffa, a novel fibroblast growth factor family member and uses therefor
WO2005048942A2 (en) 2003-11-13 2005-06-02 Pharmacia Corporation Combination therapy comprising a cox-2 inhibitor and an antineoplastic agent
US7790682B1 (en) 2003-12-02 2010-09-07 The Florida State University Research Foundation, Inc. Engineered human acidic fibroblast growth factors and associated methods
BRPI0416683A (pt) * 2003-12-10 2007-01-30 Lilly Co Eli muteìna de fator de crescimento de fibroblasto de humano 21 (fgf-21), ou um seu peptìdeo biologicamente ativo, polinucleotìdeo, vetor de expressão, célula hospedeira, processo para produzir um polipeptìdeo, composição farmacêutica, método para tratar um paciente, e, uso da muteìna fgf-21
EP1634877B1 (en) * 2004-08-17 2011-06-22 Simpson Biotech Co., Ltd. Mixture and compounds from mycelia of antrodia camphorata and use thereof
US7595296B1 (en) 2006-11-09 2009-09-29 Florida State University Research Foundation, Inc. Mutant polypeptides of fibroblast growth factor 1
US7659379B1 (en) 2007-05-24 2010-02-09 Florida State University Research Foundation, Inc. Mutants of human fibroblast growth factor having increased stability and/or mitogenic potency
NZ601868A (en) * 2008-01-22 2014-05-30 Araim Pharmaceuticals Inc Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
US8461111B2 (en) 2009-05-20 2013-06-11 Florida State University Research Foundation Fibroblast growth factor mutants having improved functional half-life and methods of their use
US20110224404A1 (en) 2010-03-11 2011-09-15 Florida State University Research Foundation Method for development of a peptide building block useful for de novo protein design
US9006400B2 (en) * 2011-09-26 2015-04-14 Novartis Ag Fibroblast growth factor-21-Fc fusion proteins
US20150253308A1 (en) * 2013-05-03 2015-09-10 Orasis Compositions and methods of treating glaucoma
WO2015048188A2 (en) * 2013-09-25 2015-04-02 Trefoil Therapeutics, Llc Modified fibroblast growth factors for the treatment of ocular disorders
TWI634898B (zh) * 2013-10-07 2018-09-11 雅祥生技醫藥股份有限公司 經修飾之人類酸性纖維母細胞生長因子及其組合物
US20150104494A1 (en) * 2013-10-11 2015-04-16 Ohio State Innovation Foundation Methods for repair of ear canal tissue defects
JP6621752B2 (ja) 2013-10-21 2019-12-18 ソーク インスティテュート フォー バイオロジカル スタディーズ 変異した線維芽細胞増殖因子（ｆｇｆ）１および使用方法
WO2015198175A1 (en) 2014-06-27 2015-12-30 Florida State University Research Foundation, Inc. Design of fgf-1 mutants to effectively eliminate reactive cysteine residues
WO2016172153A2 (en) 2015-04-20 2016-10-27 Salk Institute For Biological Studies Fibroblast growth factor (fgf) 1 with mutation in the heparin binding domain and methods of use to reduce blood glucose
CA2983268A1 (en) * 2015-04-20 2016-10-27 Salk Institute For Biological Studies Fibroblast growth factor (fgf) 1 mutants and methods of use to reduce blood glucose
EP3336178B1 (en) * 2015-08-13 2020-03-18 Fujifilm Corporation Method for culturing pluripotent stem cells, method for manufacturing culture vessel, culture vessel, and scaffold material for culturing cells
EP4621067A3 (en) 2017-05-05 2025-11-19 Trefoil Therapeutics, Inc. Recombinant modified fibroblast growth factors and therapeutic uses thereof

Also Published As

Publication number Publication date
AU2018261021B2 (en) 2024-09-12
US11479591B2 (en) 2022-10-25
JP2020518287A (ja) 2020-06-25
EP3619324A2 (en) 2020-03-11
ES3041527T3 (en) 2025-11-12
EP3619324B1 (en) 2025-07-09
US20230130851A1 (en) 2023-04-27
BR112019023260A2 (pt) 2022-02-22
RU2019139358A (ru) 2021-06-07
US20200190158A1 (en) 2020-06-18
DK3619324T3 (da) 2025-09-22
CA3062473A1 (en) 2018-11-08
JP2024112824A (ja) 2024-08-21
WO2018204847A2 (en) 2018-11-08
EP4621067A3 (en) 2025-11-19
KR20200078425A (ko) 2020-07-01
EP3619324A4 (en) 2020-12-30
RU2019139358A3 (enExample) 2021-08-26
AU2018261021A1 (en) 2019-12-12
CN111148755A (zh) 2020-05-12
EP4621067A2 (en) 2025-09-24

Similar Documents

Publication Publication Date Title
MX2019013210A (es) Factores de crecimiento recombinantes modificados de fibroblastos y usos terapéuticos de los mismos.
IL281192A (en) Interleukin-2 polypeptide conjugates and uses thereof
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
SG10201805246XA (en) Approximated parameter adaptation
MX2017004488A (es) Composiciones farmaceuticas que comprenden variantes peptidicos y metodos para su uso.
MX2021013417A (es) Polipeptidos de union a la proteina del miembro a de la familia 12 del dominio de lectina tipo c (clec12a) y sus usos.
MX2019013363A (es) Microparticulas de liberacion extendida y suspensiones de las mismas para terapia medica.
PH12021550289A1 (en) Ox40-binding polypeptides and uses thereof
MX2021012659A (es) Composiciones de seda para el cuidado del cabello.
AU201815816S (en) Inhaler
PL3618848T3 (pl) Biologicznie aktywne kompleksy i ich zastosowania terapeutyczne
SG11201912799SA (en) Recombinant human-basic fibroblast growth factor (rh-bfgf) and pharmaceutical composition comprising rh-bfgf
PH12021550122A1 (en) Solubilized apyrases, methods and use
GB2600592B (en) Polypeptide and use thereof
MX2020005344A (es) Compuestos de pirazolopiridinona.
MX2020005342A (es) Compuestos de pirazolopiridinona.
MX2020004058A (es) Inhibidores de d-aminoacido oxidasa y sus usos terapeuticos.
GB201819200D0 (en) Polypeptide and uses thereof
SG11201909851SA (en) Peptide for inducing regeneration of tissue, and use thereof
IL283452A (en) Gene therapy based on fibroblast growth factor 21 (fgf21)
IL287187A (en) An artificially replaced chromosome and its use
AU2020234373A1 (en) Novel peptide and use thereof
HK40019822A (en) Recombinant modified fibroblast growth factors and therapeutic uses thereof
SG11202109383XA (en) Recombinant bacteria and uses thereof
IL284666A (en) New peptides and their uses